Apricus Biosciences, Inc.
Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2016 Financial Results Conference Call
SAN DIEGO, 2017-03-09 13:00 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's fourth quarter and full year 2016 financial results will be released on Monday, March 13, 2017 at 4:01 p.m. Eastern Time. Company management will host a conference call on Monday, March 13, 2017, at 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
To participate by telephone, please dial (855) 780-7196 (Domestic) or (631) 485-4867 (International). The conference ID number is 85861485. The live audio webcast can be accessed via the Investor Relations’ section of the Company's website atwww.apricusbio.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for 30 days following the live call.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development. Vitaros is a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan). RayVa is our product candidate in Phase 2 development for the treatment of the circulatory disorder Raynaud’s phenomenon, secondary to scleroderma, for which we own worldwide rights.
For further information on Apricus, visithttp://www.apricusbio.com.
Vitaros™ is Apricus’ trademark in the United States, which is pending registration and subject to the agreement with Allergan. Vitaros®is a registered trademark of NexMed International Limited, and will be assigned to Ferring B.V. worldwide, excluding the United States. RayVa™ is Apricus’ trademark, which is registered in certain countries throughout the world and pending registration in the United States.
CONTACT: Institutional / Retail Investors: Matthew Beck
The Trout Group LLC
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
AMMO, Inc.12.12.2017 15:01 | pressemeddelelse
Ammo Incorporated Releases STREAK Visual Ammunition
Z-Wave Alliance12.12.2017 15:01 | pressemeddelelse
Global Smart Lock Leader ASSA ABLOY joins Z-Wave Alliance Board of Directors
Neato Robotics12.12.2017 15:01 | pressemeddelelse
Neato Appoints New CEO Matt Petersen
Williams Scotsman12.12.2017 14:07 | pressemeddelelse
Williams Scotsman to Acquire Acton Mobile
Resverlogix Corp12.12.2017 13:32 | pressemeddelelse
Nature's Recent Scientific Reports Publication Describes How Apabetalone May Be a Powerful Agent Against HIV-1
Institutional Limited Partners Association12.12.2017 13:01 | pressemeddelelse
ILPA Issues Model Subscription Agreement for Private Equity Funds
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum